Updates in Thalassemia by Hassan, Tamer & Zakaria, Marwa
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books









Beta-thalassemia is a genetic disease caused by mutations in the β-globin 
gene, resulting in partial or complete deficiency of β-chain. Deficiency of 
β-chain was accompanied by excess unmatched α-globin chains with subsequent 
dyserythropoiesis, oxidative stress, and chronic anemia. The main therapeutic option 
is blood transfusion that improves the anemic status but unfortunately exacerbates 
iron overload status. Till now, the only curative measure is allo-hematopoietic stem 
cell transplantation. New diagnostic and therapeutic modalities are now available. 
These include the preimplantation genetic diagnosis and new tools in the assessment 
of iron overload. Also, new therapeutic options aimed at different targets are being 
developed; for example, therapies that stimulate the synthesis of γ-globin and reduce 
the synthesis of α-globin, as well as the iron excess, dyserythropoiesis, and oxidative 
stress. However, the most likely ideal approach is efficient prevention, through 
genetic counseling, carrier detection, and prenatal diagnosis.
Keywords: β-thalassemia, genetic diagnosis, gene therapy, gene editing, new iron 
chelators, HSCT
1. Introduction
1.1 Updates in diagnosis
1.1.1 Preimplantation genetic diagnosis
Prenatal diagnosis (PND) services are the best practices to control prevalence of 
disease. Wide spread practicing of PND proved effective in reducing the number of 
new cases but on the other hand high abortion rate is hided, which ethically unaccepted 
and for many couples is not a suitable choice. Preimplantation genetic diagnosis is 
considered in a similar fashion to prenatal diagnosis (PGD) and is a strong alternative 
to conventional PND. PGD means genetic profiling of embryos prior to implantation 
(embryo profiling). Its main advantage is that it avoids selective pregnancy termination 
as the method makes it highly likely that the baby will be free of the disease under 
consideration. At present PGD is the only abortion free fetal diagnostic process [1].
The most important indications of PGD [1] are:
• monogenic disorders, e.g., Thalassemias;
• HLA matching (savior baby);




Technical aspects (Figure 1) [2]:
1. obtaining embryos (assisted reproductive technology)
• controlled ovarian stimulation (COH) to obtain large number of oocytes and
• ICSI/IVF;
2. obtaining biopsy (blastomere or blastocyst biopsy);
3. genetic analysis techniques (PCR, FISH); and
4. embryo transfer and cryopreservation of surplus embryos.
Mutation testing:
PGD method to diagnose beta thalassemia was initially reported in 1998 and 
used either denaturing gradient gel electrophoresis or restriction enzyme digestion 
methods to perform the mutation analysis. The possibility of misdiagnosis due to 
allele drop out (ADO) and DNA contamination is considered to be the major prob-
lems associated with preimplantation genetic diagnosis [3]. Recently, the European 
Society of Human Reproduction and Technology (ESHRE) recommends doing 
both direct and indirect mutation testing using short tandem repeat (STR) linkage 
analysis to achieve the highest accuracy rate [4].
1.1.2 Assessment of iron overload in thalassemia
a. Well established methods for assessment of iron overload in thalassemia [5]:
• serum ferritin;
• liver biopsy for liver iron content (LIC);
• echocardiography, MUGA for cardiac iron; and
• MRI T2* for LIC and cardiac iron.
b. New methods—monitoring of liver iron overload by SQUID:
• Superconducting QUantum Interference Device (SQUID) has been recently 
introduced as an integral part of thalassemia care in few centers worldwide. 
The SQUID allows the thalassemia team to monitor iron concentration in the 
livers of patients and gives them a reliable tool to help adjust medication in 
order to avoid serious complications [6].
Figure 1. 
Technical steps of PGD [2].
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Mechanism of action of SQUID:
SQUID has high-power magnetic field. Iron interferes with the field and changes 
in the field are detected [6].
Advantages and disadvantages of SQUID:
Advantages and disadvantages of SQUID are listed in Table 1 [6].
1.2 Updates in treatment
1.2.1 Gene therapy
The first obstacle against gene therapy was the extremely complex regulation of 
the globin genes. The second and equally important obstacle has been the lack of an 
optimal vector for gene transfer into quiescent hematopoietic stem cells (HSC) [7].
The first successful gene therapy for β-thalassemia major was in 2007. The 
process is as follow: autologous HSCs are harvested from the patient and then 
genetically modified with a lentiviral vector expressing a normal globin gene. After 
the patient has undergone appropriate conditioning therapy to destroy existing 
defective HSCs, the modified HSCTs are reintroduced to the patient [8].
Two large clinical trials have been recently conducted. The first one was entitled 
“ß-Thalassemia Major with Autologous CD34+ Hematopoietic Progenitor Cells 
Transduced with TNS9.3.55 a Lentiviral Vector Encoding the Normal Human 
ß-Globin Gene.” This trial was sponsored by Memorial Sloan Kettering Cancer 
Center. The second one was entitled “A Study Evaluating the Efficacy and Safety of 
the LentiGlobin® BB305 Drug Product in Subjects with Transfusion-Dependent 
β-Thalassemia, who do Not Have a β0/β0 Genotype.” It was sponsored by bluebird 
bio. Expected success awaits these clinical trials (Figure 2) [9].
1.2.2 Gene editing
A newer approach employs genome editing techniques, such as transcription 
activator-like effectors nucleases (TALEN), zinc finger nucleases (ZFN), or the 
clustered regularly interspaced short palindromic repeats (CRISPR) with Cas9 nuclease 
system. They replace the target single-mutation sites with the correct sequence, 
restoring the functional gene configuration. Producing a sufficiently large number of 
corrected genes is the major challenge with this new approach (Figure 3) [7].
1.2.3 Targeting ineffective erythropoiesis
A large number of preclinical and early clinical studies investigating 
erythropoiesis modulators are currently studied. These modulators include 
Advantages Disadvantages
Linear correlation with LIC assessed by liver biopsy Indirect measure of LIC
May be repeated frequently Limited availability
High cost
Highly specialized: needs dedicated technician
May underestimate LIC levels
Table 1. 




Gene therapy of beta thalassemia [9].
Figure 3. 
Gene editing of beta thalassemia [7].
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TGF-β-like molecules or inhibitors of JAK2, Foxo3 activators, HRI-Eif2ap 
stimulators, Prx-2 activators, HO-1 inhibitors, Hsp-70 chaperone induction 
and pyruvate kinase activation. These modulators could soon revolutionize the 
treatment of β-thalassemia and related disorders [10].
Activins, members of TGF-β family signaling, are crucial regulators of 
hematopoiesis and modulate various cellular responses such as differentiation, 
proliferation, migration, and apoptosis. They were observed to ameliorate hematologic 
parameters and improve hematopoiesis in preclinical and early clinical studies [11].
JAK2 plays an important role in the progression and worsening of ineffective 
erythropoiesis. Drugs inhibiting JAK2 activity could reverse ineffective 
erythropoiesis and splenomegaly [12].
1.2.4 Manipulating iron metabolism
Hepcidin is the central regulator of iron homeostasis. Hepcidin inhibitors, 
e.g., ERFE inhibitors are now extensively studied as a possible future treatment 
of iron overload. Induction of iron restriction by means of transferrin infusions, 
minihepcidins, or manipulation of the hepcidin pathway prevents iron overload, 
redistributes iron from parenchymal cells to macrophage stores, and partially 
controls anemia in β-thalassemic mice [13].
1.2.5 New formulation of iron chelators
Patients with transfusional iron overload usually require iron chelation therapy 
(ICT) to help decrease the iron burden and to prevent and/or delay long-term 
complications associated with iron deposition in tissues [14]. There are currently 
three available iron chelators.
1.2.5.1 Deferoxamine
DFO is a hexadentate iron chelator that binds iron in 1:1 complexes. It is given 
subcutaneously using a pump or intravenously as it is not absorbed orally. The dose 
ranges from 20 to 50 mg/kg/day. Though it is an effective drug, limited compliance 
was reported due to the inconvenience of parenteral administration as well as 
infectious complications [14].
1.2.5.2 Deferiprone
DFP was the first oral iron chelator to be used for transfusional iron overload. 
DFP is a bidentate iron chelator that forms 3:1 complexes. The dose ranges from 75 
to 100 mg/kg/day divided over three doses. Treatment with DFP was associated 
with lower myocardial iron deposition compared to deferoxamine. The most 
common adverse effects of DFP include GIT disturbances, elevated liver enzymes 
and arthropathy. The most serious adverse event was neutropenia that was 
recovered after temporary discontinuation of treatment [14].
1.2.5.3 Deferasirox
DFX is another iron chelator. It is a tridentate that forms 2:1 complexes. The 
dose ranges from 20 to 40 mg/kg/day. DFX is a long acting iron chelator. It is given 
once daily which is convenient to most patients. It lacks the DFP’s potentially life-
threatening adverse effect of agranulocytosis. Patient Compliance and adherence to 
long-term chelation therapy in patients with transfusion-dependent β-thalassemia 
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is challenging and critical to prevent iron overload-related complications. Thanks to 
oral iron chelators formulations that allow better compliance and improve patients 
and parents’ adherence to the drugs. Once-daily deferasirox dispersible tablets (DT) 
have proven long-term efficacy and safety in patients ≥2 years old with chronic 
transfusional iron overload. However, barriers to optimal adherence remain, 
including palatability, preparation time, and requirements for fasting state. A new 
film-coated tablet (FCT) formulation was developed, swallowed once daily (whole/
crushed) with/without a light meal [15]. Key differences between deferasirox 
dispersible and film coated tablets are listed in Table 2.
1.2.5.4 Combined iron chelators
Combined DFO and DFP chelation therapy was introduced to manage iron overload 
in patients with suboptimal chelation with maximum DFP doses. A shuttle mechanism 
was proposed to explain the synergistic effect of DFP and DFO. DFP enters cells due to 
its low molecular weight and removes iron, and then passes it on to DFO to be excreted 
in urine and stool. Other combinations like DFX & DFO and DFX & DFP were used to 
maximize efficacy, improve compliance and minimize the side effects [14].
1.2.6 Fetal hemoglobin induction
The main pathophysiological determinant of the severity of β-thalassemia 
syndromes is the extent of α/non-α globin chain imbalance. Thus in β-thalassemia, 
pharmacologically induced increase in γ-globin chains would be expected to 
decrease globin chain imbalance with consequent amelioration of clinical manifes-
tation. Increased production of the fetal γ-globin can bind the excess α-chains to 
produce fetal hemoglobin and hence improve α/β-globin chain imbalance leading 
to more effective erythropoiesis. This partly explains the more favorable phenotype 
in some patients with β-thalassemia intermedia and hemoglobin E/β-thalassemia 
compared with transfusion-dependent β-thalassemia major [16].
Several pharmacologic compounds including: 5-azacytidine, decitabine, 
hydroxyurea (HU), butyrate (short-chain fatty acids), erythropoietin and short 
chain fatty acid derivatives (SCFAD) as fetal hemoglobin-inducing agents had 
encouraging results in clinical trials [16].
1.2.7 Haploidentical hematopoietic stem cell transplantation
Haploidentical transplant approach have a crucial clinical significance in 
patients with beta thalassemia major as it provides a graft source to almost all 
patients who do not have an HLA-matched donors. Haploidentical HSCT is always 
available and parents of children are highly motivated. Haploidentical means 50% 
identity and the problem is the subsequent high risk of graft versus host disease 
(GVHD) caused by donor T cells. Successful haploidentical HSCT depends on 
effective removal of donor T cells [17].
Methods of T-Cell depletion [17]:
1. CD34+ positive selection with immunomagnetic separation which leads to 
enrichment of stem cells;
2. CD3 depletion with immunomagnetic separation which leads to specific 
 reduction of T cells; and
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Dispersible tablet [EXJADE] Film-coated tablet [JADENU]
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• Film-coated blue oval tablet
 ◯ 90 mg (light blue)
 ◯ 180 mg (medium blue)
 ◯ 360 mg (dark blue)
Administration • Once daily on an empty stomach 
≥30 minutes before a meal
• Stir to disperse in water, orange 
juice or apple juice
 ◯ 3.5 oz. liquid for <1 g
 ◯ 7.0 oz. liquid for ≥1 g
• Consume the suspension
• Resuspend residue in small 
amount of liquid and consume 
immediately
• Tablets should not be chewed or 
swallowed whole
• Once daily on an empty stomach 
or with a light meal (<7% fat; ~250 
calories)
• Swallow whole or crush and mix with 
soft foods such as yogurt or apple 
sauce immediately before use
Starting dose • Transfusion-dependent iron 
overload: 20 mg/kg/day
• NTDT: 10 mg/kg/day
• Transfusion-dependent iron overload: 
14 mg/kg/day
• NTDT: 7 mg/kg/day
Titration increments • Transfusion-dependent iron 
overload: 5–10 mg/kg/day
• NTDT: 5–10 mg/kg/day
• Transfusion-dependent iron overload: 
3.5–7 mg/kg/day
• NTDT: 3.5–7 mg/kg/day
Maximum dose • Transfusion-dependent iron 
overload: 40 mg/kg/day
• NTDT: 20 mg/kg/day




Deferasirox formulations: Key differences.
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